Study confirms Canvas Dx reduces time to autism diagnosis in real-world settings

Study confirms Canvas Dx reduces time to autism diagnosis in real-world settings

Study confirms Canvas Dx reduces time to autism diagnosis in real-world settings

The majority of families who have concerns about their children’s potential for developmental delay and may notice early signs of autism face long waitlists and a costly evaluation process on their path to answers and care.

Our recent Waitlist Crisis Report revealed many of the factors that are contributing to these detrimental delays in evaluation and early interventions, including too few specialists to manage the increasing demand for evaluations, cumbersome and time-consuming processes, and a lack of a standard of care diagnostic.

We at Cognoa are dedicated to equipping the large primary care workforce to take on a larger share of the growing demand for evaluations that specialists are facing, as well as streamlining the diagnostic process for autism for both specialists and primary care. Canvas Dx is designed to fulfill both of these needs, reducing wait times and making the path to care more efficient.

We recently published novel data confirming the efficacy of Canvas Dx in real-world settings–including both primary care and specialists. With quick and highly accurate outputs, Canvas Dx was able to shorten the time to autism diagnosis by 1 year, getting children that much closer to beginning early interventions sooner, when they can have the greatest lifelong impact.

At the October 2023 annual meeting of American Academy of Child and Adolescent Psychiatry (AACAP), Pediatric Neurologist and Cognoa CEO Dr. Sharief Taraman presented breaking real-world data confirming the efficacy of Canvas Dx:

  • The study included 124 children across 15 states
  • Replication of the high performance metrics that have published in clinical studies of Canvas Dx was confirmed under real-world conditions
  • Compared to the clinical reference standard, Canvas Dx had a negative predictive value (NPV) of 95.2% (20/21; 95% CI, 76.2-99.9) and a positive predictive value (PPV) of 94.4% (51/54; 95% CI, 84.6-98.8), with 60.5% (75/124; 95% CI, 51.3-69.1) receiving a determinate (positive or negative for autism) result.
  • Children using Canvas Dx received a positive for autism output over 1 year earlier than the current median age of diagnosis in the United States.

Read the full text of the article at the Journal of the American Academy of Child and Adolescent Psychiatry.

Canvas Dx is the first FDA authorized diagnostic that equips providers to make rapid, accurate, and unbiased developmental evaluations and autism diagnosis —- in days — not months or years.

Developed for use in both primary care and specialist settings, Canvas Dx not only makes the process of evaluation of autism much more efficient and cost effective, it also vastly expands the network of physicians who can diagnose autism and give kids access to the early, life-changing interventions they need.

See more of our research and data behind our robust clinical validation, efficiency and cost-savings.